SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 37,000 shares, an increase of 38.6% from the November 30th total of 26,700 shares. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.1% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.40.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock traded up $0.17 during midday trading on Friday, hitting $3.36. 63,955 shares of the company were exchanged, compared to its average volume of 62,102. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market cap of $219.66 million, a P/E ratio of -3.08 and a beta of 0.99. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $7.37. The firm has a 50 day simple moving average of $3.39 and a 200-day simple moving average of $3.83.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. During the same quarter last year, the company earned ($0.21) earnings per share. Research analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. grew its holdings in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares during the period. Green Alpha Advisors LLC acquired a new stake in shares of SOPHiA GENETICS during the third quarter worth $79,000. Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 57.5% in the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Banque Cantonale Vaudoise increased its holdings in SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock valued at $55,000 after purchasing an additional 9,000 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.